loading
前日終値:
$4.43
開ける:
$4.48
24時間の取引高:
20,654
Relative Volume:
0.03
時価総額:
$21.66M
収益:
-
当期純損益:
$-60.61M
株価収益率:
-4.9778
EPS:
-0.9
ネットキャッシュフロー:
$-22.91M
1週間 パフォーマンス:
+12.00%
1か月 パフォーマンス:
-14.67%
6か月 パフォーマンス:
+2,018%
1年 パフォーマンス:
+686.10%
1日の値動き範囲:
Value
$4.36
$4.64
1週間の範囲:
Value
$4.01
$4.64
52週間の値動き範囲:
Value
$0.0815
$7.7699

Bioline Rx Ltd Adr Stock (BLRX) Company Profile

Name
名前
Bioline Rx Ltd Adr
Name
セクター
Healthcare (1175)
Name
電話
-
Name
住所
-
Name
職員
28
Name
Twitter
Name
次回の収益日
2025-03-26
Name
最新のSEC提出書
Name
BLRX's Discussions on Twitter

BLRX を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Biotechnology icon
BLRX
Bioline Rx Ltd Adr
4.39 21.66M 0 -60.61M -22.91M -0.90
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
444.42 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
520.63 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
325.01 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
544.75 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
240.59 28.51B 3.81B -644.79M -669.77M -6.24

Bioline Rx Ltd Adr Stock (BLRX) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2017-05-18 アップグレード Maxim Group Hold → Buy
2017-02-13 開始されました Rodman & Renshaw Buy
2016-08-12 ダウングレード Maxim Group Buy → Hold
2015-08-17 繰り返されました Maxim Group Buy
2015-07-27 繰り返されました ROTH Capital Buy
2015-06-22 開始されました JMP Securities Mkt Outperform
すべてを表示

Bioline Rx Ltd Adr (BLRX) 最新ニュース

pulisher
Jun 17, 2025

Promising Phase 2 Trial Results Drive Buy Rating for BioLine RX in mPDAC Treatment - TipRanks

Jun 17, 2025
pulisher
Jun 04, 2025

BioLineRx ADR: Positive Earnings Call Highlights and Challenges - MSN

Jun 04, 2025
pulisher
May 31, 2025

BioLineRx upgraded to Buy from Hold at JonesResearch - Yahoo Finance

May 31, 2025
pulisher
May 31, 2025

BioLineRx reports promising pancreatic cancer trial data By Investing.com - Investing.com South Africa

May 31, 2025
pulisher
May 30, 2025

BioLineRx Stock Jumps On Positive Data from Pilot Phase Of Pancreatic Cancer Drug Trial: Retail Cheers The ‘Buy’ Rating By Stocktwits - Investing.com India

May 30, 2025
pulisher
May 30, 2025

BioLineRx announces new data from Phase 2 combination trial of motixafortide - TipRanks

May 30, 2025
pulisher
May 30, 2025

Jones Trading raises BioLineRx stock rating, targets $12 By Investing.com - Investing.com South Africa

May 30, 2025
pulisher
May 30, 2025

Jones Trading raises BioLineRx stock rating, targets $12 - Investing.com India

May 30, 2025
pulisher
May 30, 2025

BioLineRx Presents Promising Phase 2 Data at ASCO 2025 for Pancreatic Cancer Trial - TipRanks

May 30, 2025
pulisher
May 30, 2025

BioLineRx reports promising pancreatic cancer trial data - Investing.com

May 30, 2025
pulisher
May 29, 2025

JonesTrading Reaffirms Their Hold Rating on Bioline RX Ltd Sponsored ADR (BLRX) - The Globe and Mail

May 29, 2025
pulisher
May 28, 2025

Jones Trading maintains Hold on BioLineRx stock amid royalty prospects - Investing.com India

May 28, 2025
pulisher
May 28, 2025

Jones Trading maintains Hold on BioLineRx stock amid royalty prospects By Investing.com - Investing.com South Africa

May 28, 2025
pulisher
May 28, 2025

H.C. Wainwright Maintains Buy Rating, $26 Target on BioLineRx Stock - Investing.com

May 28, 2025
pulisher
May 28, 2025

H.C. Wainwright Maintains Buy Rating, $26 Target on BioLineRx Stock By Investing.com - Investing.com South Africa

May 28, 2025
pulisher
May 28, 2025

BioLineRx: Strong Financials and Promising Clinical Developments Drive Buy Rating - TipRanks

May 28, 2025
pulisher
May 27, 2025

BioLineRx Ltd. Reports Q1 2025 Financial Results - TipRanks

May 27, 2025
pulisher
May 27, 2025

BioLineRx Q1 Earnings Rise Despite Fall In Revenue: Retail Stays Super Confident By Stocktwits - Investing.com India

May 27, 2025
pulisher
May 27, 2025

BioLineRx Reports Q1 2025 Financial Results and Strategic Updates - TipRanks

May 27, 2025
pulisher
May 27, 2025

Options Volatility and Implied Earnings Moves Today, May 27, 2025 - TipRanks

May 27, 2025
pulisher
May 23, 2025

BioLineRx Ltd. Schedules Annual Shareholder Meeting for June 2025 - TipRanks

May 23, 2025
pulisher
May 09, 2025

Analysts Offer Insights on Healthcare Companies: VYNE Therapeutics (VYNE) and CVRx (CVRX) - The Globe and Mail

May 09, 2025
pulisher
Apr 01, 2025

BioLineRx stock rating cut to Hold at Jones Trading - Investing.com

Apr 01, 2025
pulisher
Apr 01, 2025

BLRX stock touches 52-week low at $2.85 amid sharp annual decline - Investing.com

Apr 01, 2025
pulisher
Apr 01, 2025

H.C. Wainwright raises BioLineRx stock target to $26 - Investing.com India

Apr 01, 2025
pulisher
Apr 01, 2025

BioLineRx Ltd. Reports 2024 Financial Results and Strategic Progress - TipRanks

Apr 01, 2025
pulisher
Mar 31, 2025

BioLineRx Earnings Call: Strategic Shifts and Growth - TipRanks

Mar 31, 2025
pulisher
Mar 31, 2025

BioLineRx price target adjusted to $26 at H.C. Wainwright after reverse split - TipRanks

Mar 31, 2025
pulisher
Mar 31, 2025

Options Volatility and Implied Earnings Moves This Week, March 31 – April 03, 2025 - The Globe and Mail

Mar 31, 2025
pulisher
Mar 31, 2025

BioLineRx Reports Strong 2024 Financial Results and Strategic Advancements - TipRanks

Mar 31, 2025
pulisher
Mar 31, 2025

Options Volatility and Implied Earnings Moves Today, March 31, 2025 - TipRanks

Mar 31, 2025
pulisher
Mar 07, 2025

Bioline RX Ltd Sponsored ADR to Host Earnings Call - ACCESS Newswire

Mar 07, 2025
pulisher
Feb 27, 2025

Investor Network: Bioline RX Ltd Sponsored ADR to Host Earnings Call - ACCESS Newswire

Feb 27, 2025
pulisher
Feb 19, 2025

BLRX: Aphexda Transition Progressing - Research Tree

Feb 19, 2025
pulisher
Jan 31, 2025

BioLineRx stock hits 52-week low at $3.24 amid sharp decline - Investing.com India

Jan 31, 2025
pulisher
Jan 21, 2025

BioLineRx announces strategic shift with licensing deals - Investing.com

Jan 21, 2025
pulisher
Jan 21, 2025

BioLineRx Outlines Strategic Vision and Financial Outlook After Key Licensing Deals - TipRanks

Jan 21, 2025
pulisher
Jan 17, 2025

BioLineRx Adjusts ADS Ratio to Maintain Nasdaq Listing - TipRanks

Jan 17, 2025
pulisher
Jan 17, 2025

BioLineRx Announces 1:40 ADS Ratio Change, Confirms $29.5M Cash Runway Through 2026 - Stock Titan

Jan 17, 2025
pulisher
Jan 13, 2025

BioLineRx stock touches 52-week low at $0.14 amid downturn - Investing.com India

Jan 13, 2025
pulisher
Jan 13, 2025

BioLineRx stock touches 52-week low at $0.14 amid downturn By Investing.com - Investing.com South Africa

Jan 13, 2025
pulisher
Jan 07, 2025

BiolineRx Announces Major Direct Offering to Bolster Operations - TipRanks

Jan 07, 2025
pulisher
Jan 06, 2025

BioLineRx stock plunges to 52-week low of $0.19 amid market challenges - Investing.com

Jan 06, 2025
pulisher
Jan 06, 2025

BioLineRx Announces $10 Million Direct Offering to Fuel Growth - TipRanks

Jan 06, 2025
pulisher
Jan 06, 2025

BioLineRx Raises $10M in Direct Offering at $0.20 Per ADS with Matching Warrants - Stock Titan

Jan 06, 2025
pulisher
Dec 16, 2024

BioLineRx stock hits 52-week low at $0.21 amid market challenges - Investing.com

Dec 16, 2024
pulisher
Dec 06, 2024

BioLineRx stock plunges to 52-week low, hits $0.25 - Investing.com

Dec 06, 2024

Bioline Rx Ltd Adr (BLRX) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$20.54
price up icon 0.15%
$35.94
price up icon 0.17%
$20.93
price up icon 1.69%
$100.51
price up icon 1.10%
$106.44
price down icon 0.28%
biotechnology ONC
$240.33
price down icon 0.36%
大文字化:     |  ボリューム (24 時間):